William Ho

Company: IN8Bio

Job title: CEO

Seminars:

Donor Derived Gamma-Delta T Cells; Path Towards Sold Tumor Therapies 9:30 am

Reviewing gamma-delta T cells; nonrestrictive lymphocytes that are thought to be attractive for allogeneic therapies Outlining our INB-100 phase I program, which is the first to have delivered a large bolus of ex-vivo expanded and mismatched gamma-delta T cells into lymphodepleted leukemia patients Providing safety data to advance our donor derived INB-400 program into the…Read more

day: Day One